Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNP023 versus placebo in primary IgA nephropathy
NL-OMON56184Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing LNP023 plus background ACEi/ARB with Placebo plus background ACEi/ARB (2 arms). Started Jul 2021; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NL-OMON56184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56184.